VPTDF - Ventripoint JV Begins Process to have Heart Analysis System Certified for use in COVID Patients in China
(TheNewswire)
Toronto, Ontario – TheNewswire –March 16, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ; ( OTC:VPTDF) announces that its partner, Yutian Medical Shanghai Inc. (“ Yutian ”) , has reported Chinese guidelines for thediagnosis and treatment of COVID-19 patients now require themonitoring of right-ventricular function by non-invasive techniques.
The QAS™ (VMS™ name in China) provides a safe andconvenient solution to meet that requirement. Yutian is activelyworking with regulatory bodies to have the QAS certified for COVIDpatients and has been successful in placing the QAS devices inintensive care units (ICUs). The Vice-Director of one of the leadinghospitals in Shanghai, an early adopter of this application, thinksthat they will need at least 3 QAS machines in their ICU department tobe adequately resourced for potential future COVID needs.
This innovative application substantially expands thepotential market for the QAS in uses beyond echocardiographydepartments.
About Cardiovascular Disease (CVD) inChina
Heart disease is the leading cause of death worldwide-- accounting for approximately one-third of deaths in 2019. Chinahad the highest number of heart disease deaths, followed by India,Russia, the United States and Indonesia ( 1) . China is rapidly aging due to a birth boom during the 1950sto 1970s, which was followed by a long period of imposed 1 childpolicy (2) . Currently, >16% of the population is age 60 years ormore, and this proportion is projected to increase to 35% by 2050. Thecombination of population growth and aging are expected to contributeat least another 3.4 million deaths from CVD over the next 2 decades,and related costs are projected to increase by USD $7.8 trillion from2012 to 2030 (2).
China has twice the rate of hypertension and cardiacmortality as the United States due to known risk factors. Thislatest review paper (1) recommended “risk reduction for avoidingdangerous patterns of alcohol consumption, preventing smoking,adopting diets low in added sugar, sodium, and harmful fats, andmaintaining a healthy weight beginning early in life. Effective andaffordable clinical strategies remain overlooked by health systems astargets for investments, including methods for non-invasivescreening.”
There are 34,000 hospitals in China and 1,000 newhospitals being built each year. The rate of admissions for CVD inChina is almost twice that for the United States and Europe as Chinahas been unsuccessful in changing people’s habits and so providescritical cardiac care (2).
-
(1) Global Burden of CardiovascularDiseases and Risk Factors, 1990–2019 : J Am CollCardiol . 2020,Dec, 76 (25) 2982-3021)
-
(2) Epidemiology of CardiovascularDisease in China and Opportunities for Improvement: J Am Coll Cardiol . 2019,Jun , 73 (24) 3135–3147
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
Email :gadams@ventripoint.com
Phone:519-803-6937 ??????????????
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as a result of new information, future events orotherwise, unless so required by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.